The American Medical Association (AMA) wants medical schools and residency programs to start training medical students and residents in healthcare economics.
The American Medical Association (AMA) wants medical schools and residency programs to start training medical students and residents in healthcare economics.
According to a new policy published this week, the AMA wants programs to incorporate education on the organization of healthcare delivery, modes of practice, practice settings, cost-effective use of diagnostic and treatment services, practice management, risk management, and quality assurance. These programs should also include content related to the environment and economics of medical practice in fee-for-service, managed-care, and other financing systems.
The AMA said the policy builds on its Health System Science curriculum, which launched in 2016 through its Accelerating Change in Medical Education Consortium; the AMA said knowledge about health systems is now considered the third leg of medical education that should be integrated with basic and clinical sciences education.
The move comes as patients are struggling with the costs of healthcare and specialty drugs for complex chronic diseases, rare diseases, and cancer. At the same time, physicians have seen a wave of change, as standalone clinician offices become increasingly rare, health systems combine, physician practices consolidate, and vertical integration of payers with data warehouses or retail pharmacies has become more common.
At the same time, CMS is launching new payment models and trying to incentivize physician behavior with 2-sided alternative payment reform.
“While many medical schools and residency programs currently provide students and residents with training in healthcare financing, it has become clear that future physicians require further instruction to ensure they are well-prepared to deliver care to patients in modern health systems,” said Barbara L. McAneny, MD, AMA’s immediate past president.
“Medical students and residents with a deeper understanding of cost, financing, and medical economics, will be better equipped to provide more cost-effective care that will have a positive impact for patients and the healthcare system as a whole. We will continue working to ensure future physicians are ready on day one to meet the needs of patients in the modern healthcare environment.”
The AMA includes a module on how payment models affect patient care and costs in its Graduate Medical Education Competency Education Program. The organization also said it recently published its Health System Science Review book, which includes information about value-based care and healthcare policy and economics.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.